打开APP

FDA解除勃林格殷格翰警告信——糖尿病联盟将重新提交empagliflozin新药申请

  1. 2型糖尿病
  2. empagliflozin
  3. 勃林格殷格翰
  4. 礼来

来源:生物谷 2014-06-05 09:16

FDA解除对勃林格殷格翰警告信,为勃林格-礼来糖尿病联盟重新提交empagliflozin新药申请扫清了道路。empagliflozin是一种SGLT-2抑制剂类新兴糖尿病药物。

2014年6月4日讯 /生物谷BIOON/ --勃林格殷格翰(Boehringer Ingelheim)6月3日宣布,FDA于6月2日发信告知已关闭此前发布的警告信。该警告信与勃林格殷格翰的一家药物工厂的生产问题有关。

在信中,FDA称,根据3月份的检查总结及充分考虑勃林格提交的支持性文档,已确定该公司莱茵河畔药物生产工厂的质量管理及合规系统是可以接受的。

去年春天,FDA发出了一封警告信,责骂勃林格未能尽职调查该工厂生产的数个批次活性药物成分中出现大颗粒污染事件。今年3月,FDA据此理由拒绝批准勃林格殷格翰-礼来糖尿病联盟降糖新药empagliflozin。此次遭拒,也给礼来带来了不小的麻烦,该公司已发誓今年要收获“几个”新药审批,以弥补对新药批文的长久缺憾。

此次FDA解除警告信,也为联盟再次提交empagliflozin新药申请(NDA)扫清了道路。

empagliflozin仍然代表着礼来同其他制药公司SGLT-2抑制剂类药物抗衡的最佳人选,如强生的Invokana、阿斯利康和百时美施贵宝的Farxiga(dapagliflozin)。Invokana于2013年11月获FDA批准,Farxiga则在经历长期审查推迟后也最终于今年1月获FDA批准。

Empagliflozin属于钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂类药物,目前正调查用于2型糖尿病成人患者的治疗。新兴的SGLT-2抑制剂类药物,已被证实能够阻断肾脏中葡萄糖的再吸收作用,将过多的葡萄糖排泄到体外,从而达到降低血糖水平的效果,而且该降糖效果不依赖于β细胞功能和胰岛素抵抗。(生物谷Bioon.com)

英文原文:Boehringer fixes factory, clearing way for new approval request

(Reuters) - Eli Lilly's partner in a diabetes alliance, Boehringer Ingelheim, said that U.S. regulators had given it the go-ahead for a German plant after solving quality problems, paving the way for a renewed request for approval of a drug.

The U.S. Food and Drug Administration in March declined to approve Lilly and Boehringer's experimental diabetes drug empagliflozin, citing manufacturing problems at Boehringer's headquarters, where it would be made.

Boehringer on Tuesday said it was told by the FDA that based on a March inspection, the facility's quality management and compliance systems were found to be acceptable again.

"This gives us the opportunity to renew our request for approval," a company spokesman said.

The drug is a member of a new class of diabetes medicines known as SGLT2 inhibitors, which block the kidney from reabsorbing blood sugar, thereby spurring removal of glucose through the urine. Recently approved similar medicines include Johnson & Johnson's Invokana.

Analysts surveyed by Thomson Reuters Cortellis on average expect Lilly to generate sales of more than $400 million from the drug in 2019.

The FDA issued a warning letter in May 2013 citing problems it found at the Boehringer plant during an inspection six months earlier. Among other issues, the FDA said it detected foreign particles in batches of active pharmaceutical ingredients.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->